Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

• Status: Completed
• Trial end date: 2019-08-19

Summary

This research study is studying a drug intervention as a possible treatment for lung cancer.

The drugs involved in this study are:

• Nivolumab

• Carboplatin

• Pemetrexed

• Ipilimumab

• Phase: Phase 2

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Carboplatin; Ipilimumab; Nivolumab; Pemetrexed